These insights emphasize the importance of reevaluating glucagon not only as a metabolic hormone, but also as a potential upstream driver of multi-organ complications in diabetes
Once stable, most patients have check-ins every 4-12 weeks depending on their risk profile, genetic predispositions, and whether they're on dose escalation
The SGLT2i class showed significant relative risk reduction for the prevention of the composite kidney outcomes (35%) and for hospitalization for HF (32%) compared with placebo and superior to GLP-1RA
Wettwer E, Christ T, Endig S, Rozmaritsa N, Matschke K, Lynch JJ, Pourrier M, Gibson JK, Fedida D, Knaut M, Ravens U (2013) The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation